Strategic Consulting for Biotech Commercialization & AI Implementation
Partnering with founders, investors, and changemakers to build what's next
Distilling Breakthroughs to Reach Investors & Customers: At Morpheos, we help creators, scientists, and engineers build out their vision and communicate the value of their technology to capture their audience's attention and bring them onboard with their vision.
We work with scientists, engineers, and technical founders to translate complex innovations into functional applications with clear, compelling strategy and clearly defined commercial strategy that resonates with investors, partners, and customers.
The process starts with deep listening — we directly engage with the technical team to understand the depth of the technology and fully grasp and define the technology's unique value proposition. We then work to refine and distill that complexity into a clear and efficient narrative that can (1) unify the development team around common goals, (2) draw in customers, and (3) efficiently capture the attention of investors and potential business partners.
Brandon Hogstad, Ph.D., is principal consultant and founder of Morpheos Innovation LLC, where he partners with startups, investors, and academic institutions across biotech and AI-driven platforms. He specializes in strategic commercialization, alliance management, and scientific due diligence—guiding breakthrough innovations from concept to market.
Before launching Morpheos, Brandon led drug discovery accelerator programs and high-impact collaborations at NYU Langone Health, securing partnerships with global industry leaders like Sanofi and Pfizer (including the antiviral research that contributed to Paxlovid). He later advanced AI-driven immunotherapy initiatives at Immunai, forging strategic relationships to harness single-cell genomics for precision medicine.
Brandon earned his Ph.D. in Biomedical Sciences from the Icahn School of Medicine at Mount Sinai. His contributions have appeared in top-tier journals such as Nature and the Journal of Experimental Medicine. Drawing on his broad expertise in target validation, preclinical strategy, and cutting-edge AI applications, Brandon remains committed to advancing medical science and global health through technology-driven innovation.